A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
- Registration Number
- NCT02394028
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely active Crohn's Disease (CD). The target population includes participants with CD who are refractory or intolerant to corticosteroids (CS) and/or immunosuppressant (IS) therapy and who have either not received prior anti-tumor necrosis factor (anti-TNF) therapy (TNF-naive) or who have had prior exposure to anti-TNF therapies and demonstrated inadequate responses or intolerance to anti-TNFs.
The study period will consist of a Screening Phase (up to 35 days) plus (+) a 14-week Induction Phase + a 52-week Maintenance Phase + a 12-week Safety Follow-up Phase. At Week 14 (end of Induction Phase), participants achieving a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index (CDAI) score (CDAI-70 response) without the use of rescue therapy will continue to the Maintenance Phase.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1035
- Moderately to severely active Crohn's Disease (CD) as determined by the CDAI, patient reported outcomes and endoscopically defined disease activity in the ileum and/or colon
- Intolerance, refractory disease, or no response to corticosteroids (CS), immunosuppressants (IS), or anti-TNF therapy within 5 years from screening. Participants who have not previously demonstrated inadequate response or intolerance to one or more anti-TNF therapies are eligible to participate in the study provided they are intolerant or refractory to CS or IS therapy
- Use of effective contraception as defined by the protocol
- A history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome
- Planned surgery for CD
- Ileostomy or colostomy
- Has received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, and efalizumab, as stated in the protocol)
- Any prior treatment with ustekinumab within 14 weeks prior to randomization
- Chronic hepatitis B or C infection, human immunodeficiency virus (HIV), active or latent tuberculosis (participants with prior history of Bacillus Calmette-Guérin [BCG] vaccination must pass protocol-defined screening criteria)
- Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical judgment of the investigator. Fistulas related to CD are not exclusionary
- Any prior treatment with anti-adhesion molecules (e.g., anti-mucosal addressin cell adhesion molecule [anti-MAdCAM-1])
- Any major episode of infection requiring treatment with intravenous antibiotics ≤8 weeks prior to screening or oral antibiotics ≤4 weeks prior to screening. Treatment with antibiotics as adjunctive therapy for CD in the absence of documented infection is not exclusionary
- Hospitalization (other than for elective reasons) within 4 weeks prior to randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg Etrolizumab Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg Etrolizumab Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg Etrolizumab Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg Etrolizumab Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg Etrolizumab Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg Etrolizumab Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg Placebo Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 1 (Exploratory): Placebo Placebo Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking. Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg Placebo Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg Placebo Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg Placebo Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg Placebo Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg Placebo Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12. Induction Phase - Cohort 3 (Pivotal): Placebo Placebo Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking. Maintenance Phase - Placebo Responders: Placebo Placebo Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64. Maintenance Phase - Etrolizumab Responders: Placebo Placebo Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64. Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg Etrolizumab Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
- Primary Outcome Measures
Name Time Method Induction Phase: Cohort 1: Percentage of Participants With Endoscopic Improvement at Week 14 Week 14 Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score.
Induction Phase: Cohort 2 and 3: Percentage of Participants With Clinical Remission at Week 14 Week 14 Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Maintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 66 Week 66 Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Maintenance phase participants were evaluated.
Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14 Week 14 Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Induction Phase: Cohort 2 and 3: Percentage of Participants With Endoscopic Improvement at Week 14 Week 14 Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score.
Maintenance Phase: Percentage of Participants With Clinical Remission at Week 66 Baseline and Week 66 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Maintenance phase participants were evaluated.
- Secondary Outcome Measures
Name Time Method Induction Phase: Cohort 1: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score Greater Than (>)1, at Week 14 Week 14 Endoscopic Remission is defined as SES-CD total score \<=4 (\<=2 for ileal only patients), with no segment having a subcategory score \>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.
Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 6 Week 6 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Induction Phase: Cohort 2 and 3: Percentage of Participants With Clinical Remission at Week 6 Week 6 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Maintenance Phase: Percentage of Participants With Clinical Remission at Week 66, Among Those Who Achieved Clinical Remission at Week 14 Baseline, Weeks 14 and 66 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Induction Phase Cohorts are not includedMaintenance Phase: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score >1, at Week 66 Week 66 Endoscopic Remission is defined as SES-CD total score \<=4 (\<=2 for ileal only patients), with no segment having a subcategory score \>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.
Maintenance Phase: Percentage of Participants With Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those Who Were Receiving Corticosteroids at Baseline Baseline and from Week 14 up to Week 66 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Percentage of participants with clinical remission who will be off corticosteroids for at least 24 weeks prior to Week 66 will be reported.
Induction Phase Cohorts are not includedInduction Phase: Cohort 2 and 3: Percentage of Participants With SES-CD Score ≤4 (≤2 for Ileal Participants), With No Segment Having a Subcategory Score Greater Than (>)1, at Week 14 Week 14 Endoscopic Remission is defined as SES-CD total score \<=4 (\<=2 for ileal only patients), with no segment having a subcategory score \>1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity.
Maintenance Phase: Change From Baseline in CD-PRO/SS Score at Week 66 Baseline and Week 66 CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.
Overall Number of Participants Who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0) From Baseline up to Week 78 Investigator text for AEs is coded using MedDRA version 24.0. For participants counts, multiple occurrences of AEs in the same category for an individual are counted only once. For event counts, multiple occurrences of AEs in the same category for an individual are counted separately. Severity Grades from 1 to 5.
Overall Number of Participants With Adverse Events Leading to Study Drug Discontinuation From Baseline up to Week 78 Number of participants who discontinued the study due to the adverse events is reported.
Overall Number of Participants Who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE v4.0 From Baseline up to Week 78 Investigator test for AEs is coding using MedDRA version 24.0. Injection-Site Reactions are identified by eCRF checkbox for local injection site reactions, and/or primary or secondary HLT Injection Site Reactions. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab Baseline, Pre-dose (Hour 0) on Weeks 4, 14, 24, 32, 44, 66 or early termination, 12 weeks after last dose (up to Week 78) Participants who received at least one dose of study treatment and had at least one baseline or post-baseline ATA result. Induction: treatment groups were pooled across cohorts 1-3. Maintenance: treatment group is stratified by induction dose
Induction Phase: Cohort 1: Change From Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14 Baseline and Week 14 CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.
Induction Phase: Cohort 2 and 3: Change From Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14 Baseline and Week 14 CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available.
Maintenance Phase: Percentage of Participants With Durable Clinical Remission Week 14 up to Week 66 (assessed at Weeks 24, 28, 32, 44, 56, and 66) Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Durable clinical remission was defined as clinical remission at ≥4 of the 6 in-clinic assessment visits conducted during the Maintenance Phase at Weeks 24, 28, 32, 44, 56, and 66. Induction Phase Cohorts are not included
Overall Number of Participants Who Experienced at Least One Infection-Related Serious Adverse Event From Baseline up to Week 78 Investigator text for AEs is coded using MedDRA version 24.0. Infections are identified by primary System Organ Class term 'Infections and Infestations'. The terms 'severe' and 'serious' are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs in the same category for an individual are counted only once
Overall Number of Participants Who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0 From Baseline up to Week 78 Investigator text for AEs is coded using MedDRA version 24.0. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported.
Observed Trough Serum Concentration (Ctrough) of Etrolizumab Induction Phase at Weeks 10 and 14, Maintenance Phase at Weeks 16, 24, 28, 32, 44, and 66 Serum Etrolizumab Trough Concentration
Maintenance Phase: Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 66, Among Those Who Were Receiving Corticosteroids at Baseline Baseline and Week 66 Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.
Induction Phase Cohorts are not includedMaintenance Phase: Percentage of Participants With Endoscopic Improvement at Week 66 Among Participants Who Achieved Endoscopic Improvement at Week 14 Baseline, Weeks 14 and 66 Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Induction Phase Cohorts are not included
Overall Number of Participants Who Develop Malignancies From Baseline up to Week 78 Participants with malignancies are reported. 'Malignancies are identified by SMQ Malignant and unspecified tumors (narrow)
Overall Number of Participants Who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0 From Baseline up to Week 78 Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0 are reported. Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = Death. The terms 'severe' and 'serious' are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs are counted only once per participant at the highest (worst) grade. Infections are identified by Primary System Organ Class term 'Infections and Infestations'
Trial Locations
- Locations (327)
Innovative Medical Research of South Florida
🇺🇸Aventura, Florida, United States
LKH - Universitätsklinikum der PMU Salzburg
🇦🇹Salzburg, Austria
Clinical Hospital Center Sestre Milosrdnice
🇭🇷Zagreb, Croatia
Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaza
🇭🇺Bekescsaba, Hungary
Pannonia Maganorvosi Centrum
🇭🇺Budapest, Hungary
Debreceni Egyetem
🇭🇺Debrecen, Hungary
Private Small Enterprise Medical Center Pulse
🇺🇦Vinnytsia, Ukraine
LLC Diaservis
🇺🇦Zaporizhzhia, Ukraine
MCIC MC LLC Health Clinic
🇺🇦Vinnytsia, Ukraine
Emory University Hospital
🇺🇸Atlanta, Georgia, United States
Atlanta Gastroenterology Associates
🇺🇸Atlanta, Georgia, United States
Taunton Health Centre
🇨🇦Oshawa, Ontario, Canada
Hospital Estadual Mario Covas
🇧🇷Santo Andre, SP, Brazil
"City Clinic UMHAC" EOOD
🇧🇬Sofia, Bulgaria
Hôpital Saint-Louis
🇫🇷Paris, France
West Tallinn Central Hospital
🇪🇪Tallinn, Estonia
University of Calgary
🇨🇦Calgary, Alberta, Canada
Fakultni nemocnice Ostrava
🇨🇿Ostrava - Poruba, Czechia
Klinikum der Johann Wolfgang Goethe-Universitaet
🇩🇪Frankfurt, Germany
Hospital Felicio Rocho
🇧🇷Belo Horizonte, MG, Brazil
PreventaMed, s.r.o.
🇨🇿Olomouc, Czechia
UMHAT "Sv. Ivan Rilski", EAD
🇧🇬Sofia, Bulgaria
University Hospital Center Zagreb
🇭🇷Zagreb, Croatia
The Ottawa Hospital - Riverside Campus; Gastrointestinal Clinical Research Unit
🇨🇦Ottawa, Ontario, Canada
Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital Sírio-Libanês
🇧🇷Sao Paulo, SP, Brazil
Hospital Ernesto Dornelles
🇧🇷Porto Alegre, RS, Brazil
Praxis Pesquisa Médica
🇧🇷Santo Andre, SP, Brazil
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Clinical Hospital Centre Osijek
🇭🇷Osijek, Croatia
North Estonia Medical Centre Foundation
🇪🇪Tallinn, Estonia
Tartu University Hospital
🇪🇪Tartu, Estonia
CHU Nice - Hopital de l'Archet 2
🇫🇷Nice, France
Gastroenterologie s.r.o.
🇨🇿Hradec Kralove, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Hepato-Gastroenterologie HK, s.r.o.
🇨🇿Hradec Kralove, Czechia
Vojenska nemocnice Brno
🇨🇿Brno, Czechia
UMHAT Tsaritsa Yoanna - ISUL, EAD
🇧🇬Sofia, Bulgaria
McGill University Health Centre - Glen Site
🇨🇦Montreal, Quebec, Canada
Toronto Digestive Disease Associates
🇨🇦Vaughan, Ontario, Canada
Charite-Campus Virchow Klinikum; Hepatologie und Gastroenterologie
🇩🇪Berlin, Germany
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Universitaetsklinikum Halle (Saale)
🇩🇪Halle, Germany
Fakultni nemocnice u sv. Anny v Brne
🇨🇿Brno, Czechia
Hôpital Maisonneuve - Rosemont
🇨🇦Montreal, Quebec, Canada
Pest Megyei Flor Ferenc Korhaz
🇭🇺Kistarcsa, Hungary
Haemek Medical Center
🇮🇱Afula, Israel
Soroka University Medical Centre
🇮🇱Beer Sheva, Israel
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Asst Fatebenefratelli Sacco (Fatebenefratelli)
🇮🇹Milano, Lombardia, Italy
Höpital Hautepierre; Pediatrie1
🇫🇷Strasbourg, France
Policlinico Universitario Agostino Gemelli; Farmacia
🇮🇹Roma, Lazio, Italy
Nemocnice Ceske Budejovice a.s.
🇨🇿Ceske Budejovice, Czechia
Petz Aladar Megyei Oktato Korhaz
🇭🇺Gyor, Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
🇭🇺Székesfehérvár, Hungary
Rabin Medical Center-Beilinson Campus
🇮🇱Petach Tikva, Israel
Klinikum Mannheim GmbH Universitätsklinikum
🇩🇪Mannheim, Germany
Krankenhaus Waldfriede e. V.
🇩🇪Berlin, Germany
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
CHU Amiens - Hopital Sud
🇫🇷Amiens, France
CHU Rennes - Hopital Pontchaillou
🇫🇷Rennes cedex 09, France
Pauls Stradins Clinical University Hospital
🇱🇻Rīga, Latvia
Wolfson Medical Center; Obstetrics and Gynecology
🇮🇱Holon, Israel
Holy Family Hospital
🇮🇱Nazareth, Israel
Tel Aviv Sourasky Medical Center; Pharmacy
🇮🇱Tel Aviv, Israel
Obudai Egeszsegugyi Centrum Kft.
🇭🇺Budapest, Hungary
Yeungnam Univ. Hospital
🇰🇷Daegu, Korea, Republic of
Medizinische Hochschule Hannover; Gastroenterology and Hepatology dept
🇩🇪Hannover, Germany
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Vilnius University Hospital Santariskiu Clinic, Public Institution; Cardiology
🇱🇹Vilnius, Lithuania
Zuyderland Medisch Centrum - Sittard Geleen
🇳🇱Sittard-Geleen, Netherlands
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
A.O.U. Policlinico di Modena
🇮🇹Modena, Emilia-Romagna, Italy
Hospital of Lithuanian University of Health. Sciences Kaunas Clinics
🇱🇹Kaunas, Lithuania
Ospedale Umberto I di Torino
🇮🇹Torino, Piemonte, Italy
Korea University Ansan Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Riga East Clinical University Hospital; Clinic Gailezers
🇱🇻Riga, Latvia
Clinical Research Institute
🇲🇽Tlalnepantla de Baz, Mexico CITY (federal District), Mexico
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
S.C MedLife S.A
🇷🇴Bucuresti, Romania
North Shore Hospital
🇳🇿Auckland, New Zealand
LLC "Novosibirsk GastroCenter"
🇷🇺Novosibirsk, Altaj, Russian Federation
Medical Care & Research SA de CV
🇲🇽Mérida, Yucatan, Mexico
Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj
🇵🇱Toruń, Poland
University Hospital Medical Center Bezanijska kosa
🇷🇸Belgrade, Serbia
Dr D Epstein Practice
🇿🇦Cape Town, South Africa
Clinical Center of Vojvodina
🇷🇸Novi Sad, Serbia
IBDcentrum s.r.o.
🇸🇰Bratislava, Slovakia
Maastricht University Medical Center
🇳🇱Maastricht, Netherlands
Nasz Lekarz Osrodek Badan Klinicznych
🇵🇱Bydgoszcz, Poland
Indywidualna Specjalistyczna Praktyka Lekarska
🇵🇱Lublin, Poland
Niepubliczny Zaklad Opieki Zdrowotnej SONOMED
🇵🇱Szczecin, Poland
Dunedin Public Hospital
🇳🇿Dunedin, New Zealand
EuroMediCare Szpital Specjalistyczny z Przychodnią we Wrocławiu
🇵🇱Wroclaw, Poland
Centrul de Gastroenterologie Dr. Goldis
🇷🇴Timisoara, Romania
Erasmus Medisch Centrum
🇳🇱Rotterdam, Netherlands
ETZ TweeSteden
🇳🇱Tilburg, Netherlands
SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego
🇵🇱Białystok, Poland
Elblaski Szpital Specjalistyczny z Przychodnia SP ZOZ
🇵🇱Elblag, Poland
Centrum Medyczne "MEDYK"
🇵🇱Rzeszow, Poland
Christchurch Hospital NZ
🇳🇿Christchurch, New Zealand
Centrum Zdrowia MDM
🇵🇱Warszawa, Poland
Zespó Przychodni Specjalistycznych PRIMA
🇵🇱Warszawa, Poland
Yusupov Hospital
🇷🇺Moskva, Adygeja, Russian Federation
Gabinet Lekarski, Bartosz Korczowski
🇵🇱Rzeszów, Poland
Twoja Przychodnia-Szczecinskie Centrum Medyczne
🇵🇱Szczecin, Poland
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
LexMedica Osrodek Badan Klinicznych
🇵🇱Wroclaw, Poland
Spitalul Clinic Colentina
🇷🇴Bucharest, Romania
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Kocaeli Universitesi Tip Fakultesi; Infectious Diseases
🇹🇷Kocaeli, Turkey
Acibadem Kozyatagi Hospital; Gastroenterology
🇹🇷Kozyataği, Turkey
Centro Médico Teknon
🇪🇸Barcelona, Spain
Hospital Juan Ramón Jiménez
🇪🇸Huelva, Spain
SEIHPE "Rostov SMU of MoH of RF"
🇷🇺Rostov-on-Don, Russian Federation
Hospital Universitario de Bellvitge
🇪🇸Hospitalet de Llobregat, Barcelona, Spain
General Hospital Djordje Joanovic
🇷🇸Zrenjanin, Serbia
Hacettepe University Medical Faculty; Gastroenterology
🇹🇷Ankara, Turkey
KM Management spol. s r.o.
🇸🇰Nitra, Slovakia
Crohn-Colitis Zentrum Bern - Gemeinschaftspraxis Balsiger, Seibold und Partner
🇨🇭Bern, Switzerland
Hospital Universitario de la Princesa
🇪🇸Madrid, Spain
Hospital Clínic i Provincial; Servicio de Farmacia
🇪🇸Barcelona, Spain
Ege University Medical Faculty
🇹🇷Izmir, Turkey
Evromedservis LCC
🇷🇺Pushkin, Russian Federation
CI of Kyiv RC Regional Clinical Hospital #2
🇺🇦Kyiv, KIEV Governorate, Ukraine
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Hospital Universitario Puerta de Hierro Majadahonda; Hepatology studies
🇪🇸Majadahonda, Madrid, Spain
SBEI HPE Altai StateMedicalUniversityofMoH andSD
🇷🇺Barnaul, Russian Federation
Accout Center s.r.o.
🇸🇰Šahy, Slovakia
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Reina Sofia; Medical Oncology
🇪🇸Cordoba, Spain
Inselspital-Universitaetsspital Bern
🇨🇭Bern, Switzerland
Universitätsspital Zürich
🇨🇭Zürich, Switzerland
Complejo Hospitalario de Pontevedra
🇪🇸Pontevedra, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
University Hospital Coventry
🇬🇧Coventry, United Kingdom
Royal Victoria Infirmary; Stroke unit
🇬🇧Newcastle Upon Tyne, United Kingdom
Kremenchuk first city hospital n.a. O.T. Bohaievskyi; Gastroenterology department
🇺🇦Kremenchuk, Poltava Governorate, Ukraine
University College London Hospital
🇬🇧London, United Kingdom
Medical Center of Limited Liability Company Medical Clinic Blagomed
🇺🇦Kyiv, KIEV Governorate, Ukraine
Haydarpasa Numune Training and Research Hospital; Medical Oncology
🇹🇷Istanbul, Turkey
Ivano-Frankivsk Regional Clinical Hospital
🇺🇦Ivano-Frankivsk, Kuban People's Republica, Ukraine
Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU
🇺🇦Kyiv, Ukraine
Royal Victoria Hospital
🇬🇧Belfast, United Kingdom
CI of Healthcare Kharkiv Reg Clin Hosp-Center of Med Emergency & Accident Medicine
🇺🇦Kharkiv, Kharkiv Governorate, Ukraine
RCNECRCH Dept of Surgery, SHEI Ukr BSMU
🇺🇦Chernivtsi, Podolia Governorate, Ukraine
CHI Kharkiv City Clinical Hospital #13
🇺🇦Kharkiv, Ukraine
St James University Hospital
🇬🇧Leeds, United Kingdom
Medeniyet University Goztepe Training and Research Hospital; Chest Diseases
🇹🇷Istanbul, Turkey
City Hospital #1
🇺🇦Mykolaiv, Ukraine
Lviv Regional Clinical Hospital
🇺🇦Lviv, KIEV Governorate, Ukraine
CI City Hospital #1
🇺🇦Zaporizhzhia, Tavria Okruha, Ukraine
GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
🇺🇦Kharkiv, Ukraine
Royal Devon and Exeter Hospital (Wonford)
🇬🇧Exeter, United Kingdom
Royal Berkshire Hospital
🇬🇧Reading, United Kingdom
Nottingham University Hospitals Queen's Medical Centre
🇬🇧Nottingham, United Kingdom
Methodist Hospital Research Institute
🇺🇸Houston, Texas, United States
Winnipeg Regional Health Authority
🇨🇦Winnipeg, Manitoba, Canada
Valley Gastroenterology Consultants
🇺🇸Arcadia, California, United States
University of California San Diego Medical Center
🇺🇸La Jolla, California, United States
VA Long Beach Healthcare System
🇺🇸Long Beach, California, United States
Digestive Care Associates, A Medical Corporation
🇺🇸San Carlos, California, United States
Peak Gastroenterology Associates; Gastroenterology
🇺🇸Colorado Springs, Colorado, United States
Borland-Groover Clinic
🇺🇸Jacksonville, Florida, United States
West Central Gastroenterology d/b/a Gastro Florida
🇺🇸Clearwater, Florida, United States
University of Florida College of Medicine
🇺🇸Gainesville, Florida, United States
FQL Research, LLC
🇺🇸Miramar, Florida, United States
IMIC, Inc
🇺🇸Miami Beach, Florida, United States
Shafran Gastroenterology Center
🇺🇸Winter Park, Florida, United States
Advanced Research Institute, Inc.
🇺🇸Trinity, Florida, United States
Gastrointestinal Diseases Research
🇺🇸Columbus, Georgia, United States
Atlanta Center for Gastroenterology, PC
🇺🇸Decatur, Georgia, United States
Gastroenterology Associates of Central Georgia
🇺🇸Macon, Georgia, United States
Advanced Clinical Research
🇺🇸Meridian, Idaho, United States
Gastrointestinal Specialists of Georgia, PC
🇺🇸Marietta, Georgia, United States
The University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Cotton-O'Neil Clinical Research Center, Digestive Health
🇺🇸Topeka, Kansas, United States
Carle Foundation Hospital
🇺🇸Urbana, Illinois, United States
Southwest Gastroenterology; DM Clinical Research
🇺🇸Oak Lawn, Illinois, United States
Gastroenterology Associates, LLC
🇺🇸Baton Rouge, Louisiana, United States
Louisiana Research Center, LLC
🇺🇸Shreveport, Louisiana, United States
Commonwealth Clinical Studies
🇺🇸Brockton, Massachusetts, United States
Gastroenterology Associates of Western Michigan, P.L.C.
🇺🇸Grand Rapids, Michigan, United States
Center for Digestive Health
🇺🇸Troy, Michigan, United States
Henry Ford Health System
🇺🇸West Bloomfield, Michigan, United States
University of Mississippi Medical Center; Division of Gastroenterology
🇺🇸Jackson, Mississippi, United States
Ehrhardt Clinical Research, LLC
🇺🇸Belton, Missouri, United States
Concorde Medical Group
🇺🇸New York, New York, United States
Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC)
🇺🇸New York, New York, United States
Lenox Hill Hospital
🇺🇸New York, New York, United States
Charlotte Gastroenterology and Hepatology, P.L.L.C
🇺🇸Charlotte, North Carolina, United States
Kinston Medical Specialists
🇺🇸Kinston, North Carolina, United States
Great Lakes Gastroenterology Research, LLC
🇺🇸Mentor, Ohio, United States
Great Lakes Medical Research, LLC
🇺🇸Harrisburg, Pennsylvania, United States
Innovative Clinical Research
🇺🇸Greenville, South Carolina, United States
Gastroenterology Center of the MidSouth PC
🇺🇸Germantown, Tennessee, United States
Texas Digestive Disease Consultants - Dallas
🇺🇸Dallas, Texas, United States
Baylor College of Medicine; Gastroenterology
🇺🇸Houston, Texas, United States
University of Texas Southwestern Medical Center; Internal Medicne
🇺🇸Dallas, Texas, United States
Texas Digestive Disease Consultants - Southlake
🇺🇸Southlake, Texas, United States
Tyler Research Institute, LLC
🇺🇸Tyler, Texas, United States
Ericksen Research and Development
🇺🇸Clinton, Utah, United States
Digestive Disease Institute; Virginia Mason Medical Center
🇺🇸Seattle, Washington, United States
University of Wisconsin
🇺🇸Madison, Wisconsin, United States
Hospital Italiano
🇦🇷Buenos Aires, Argentina
The Canberra Hospital
🇦🇺Garran, Australian Capital Territory, Australia
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Royal Brisbane and Women's Hospital
🇦🇺Herston, Queensland, Australia
University of the Sunshine Coast
🇦🇺Sippy Downs, Queensland, Australia
Mater Adult Hospital
🇦🇺South Brisbane, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
Monash Medical Centre Clayton
🇦🇺Clayton, Victoria, Australia
St Vincent's Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
St Frances Xavier Cabrini Hospital
🇦🇺Malvern, Victoria, Australia
Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Royal Melbourne Hospital; Department of Colorectal Medicine and Genetics
🇦🇺Parkville, Victoria, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Medizinische Universität Wien
🇦🇹Wien, Austria
CHU St Pierre (St Pierre)
🇧🇪Brussels, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
Queen Elizabeth II Health Sciences Centre; Gastroenterology Research
🇨🇦Halifax, Nova Scotia, Canada
General Hospital Pula
🇭🇷Pula, Croatia
Hopital Claude Huriez - CHU Lille
🇫🇷Lille, France
Klinicke centrum ISCARE Lighthouse
🇨🇿Praha 7, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Centre Hospitalier Lyon Sud; Service de Gastro-Enterologie
🇫🇷Pierre-Benite, France
Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH
🇩🇪Bochum, Germany
Universitätsklinikum Koeln
🇩🇪Koeln, Germany
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Pecsi Tudomanyegyetem
🇭🇺Pecs, Hungary
Azienda Ospedaliera San Camillo Forlanini
🇮🇹Roma, Lazio, Italy
Inje University Busan Paik Hospital
🇰🇷Busan, Korea, Republic of
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Yonsei University Wonju Severance Christian Hospital
🇰🇷Wonju-Si, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Amsterdam UMC, Locatie VUMC; Neurology
🇳🇱Amsterdam, Netherlands
Leids Universitair Medisch Centrum
🇳🇱Leiden, Netherlands
Amsterdam UMC Location AMC
🇳🇱Amsterdam, Netherlands
Waikato Hospital
🇳🇿Hamilton, New Zealand
ETG Kielce
🇵🇱Kielce, Poland
Allmedica Badania Kliniczne Sp z o.o. Sp K.
🇵🇱Nowy Targ, Poland
Centrum Opieki Zdrowotnej Orkan-Med
🇵🇱Ksawerow, Poland
Specjalistyczna Praktyka Lekarska Dr med. Marek Horynski; endoskopia
🇵🇱Sopot, Poland
PlanetMed sp. z o.o.
🇵🇱Wrocław, Poland
Warsaw IBD Point Profesor Kierkus
🇵🇱Warszawa, Poland
Irkutsk State Medical Academy of Continuing Education
🇷🇺Irkutsk, Russian Federation
SBIH City Clinical Hospital #31
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
Clinical Helth Centre Zvezdara
🇷🇸Belgrade, Serbia
Federal State Military Educational Institution; High Professional Education Military Medical Acad
🇷🇺St. Petersburg, Russian Federation
Endomed, s.r.o.
🇸🇰Vranov nad Topľou, Slovakia
Emmed Research
🇿🇦Pretoria, South Africa
Hospital Universitario de Fuenlabrada
🇪🇸Madrid, Spain
Acibadem Fulya Hospital; Neurology
🇹🇷Istanbul, Turkey
Gazi University Medical Faculty
🇹🇷Ankara, Turkey
CHI Prof.O.O.Shalimov Kharkiv City Clinical Hospital #2
🇺🇦Kharkiv, Kharkiv Governorate, Ukraine
Med Center of International Institute of Clinical Trials LLC; Medical Center "OK!Clinic+"
🇺🇦Kyiv, KIEV Governorate, Ukraine
ASST FATEBENEFRATELLI SACCO (Sacco)
🇮🇹Milano, Lombardia, Italy
Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)
🇮🇹Milano, Lombardia, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano (MI), Lombardia, Italy
I.R.C.C.S Policlinico San Donato
🇮🇹San Donato Milanese (MI), Lombardia, Italy
Azienda Ospedaliera Universitaria Careggi
🇮🇹Florence, Toscana, Italy
Consultants for Clinical Research Inc.
🇺🇸Cincinnati, Ohio, United States
Wellness Clinical Research Center
🇺🇸San Antonio, Texas, United States
SDG Clinical Research
🇺🇸San Diego, California, United States
University of California at San Francisco (PARENT); Gastroenterology, Hepatology & Nutrition
🇺🇸San Francisco, California, United States
Mayo Clinic - Rochester; Gastrology
🇺🇸Rochester, Minnesota, United States
Digestive Disease Specialists, Inc.
🇺🇸Oklahoma City, Oklahoma, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
University of Utah School of Medicine
🇺🇸Salt Lake City, Utah, United States
CHU de Caen - Hopital Cote de Nacre
🇫🇷Caen, France
Hôpital Beaujon
🇫🇷Clichy cedex, France
CHU NANTES - Hôtel Dieu; Pharmacy
🇫🇷Nantes, France
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - USN
🇫🇷Pessac, France
CHU du Reims - Hopital Robert Debré
🇫🇷Reims, France
CHU Saint Etienne - Hôpital Nord
🇫🇷Saint Etienne, France
Hôpital de Brabois Adultes
🇫🇷Vandoeuvre-les-nancy, France
Fairfield General Hospital
🇬🇧Manchester, United Kingdom
Addenbrooke's Hospital
🇬🇧Cambridge, United Kingdom
Queen Elizabeth Hospital
🇬🇧Kings Lynn, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Royal Wolverhampton hospital; McHale Building
🇬🇧Wolverhampton, United Kingdom
L2IP -Instituto de Pesquisas Clínicas Ltda.
🇧🇷Brasilia, DF, Brazil
Centro Digestivo de Curitiba
🇧🇷Curitiba, PR, Brazil
Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda
🇧🇷Goiânia, GO, Brazil
Hospital Universitario Clementino Fraga Filho - UFRJ; Gastroenterologia
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital São Vicente de Paulo; Institute of Education and Reseach / Cardiovascular Research Unit
🇧🇷Passo Fundo, RS, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Pesquisare Saúde Sociedade Simples
🇧🇷Santo Andre, SP, Brazil
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
🇧🇷Botucatu, SP, Brazil
Hospital Sao Paulo
🇧🇷Sao Paulo, SP, Brazil
Hospital do Servidor Público Estadual/HSPE-SP
🇧🇷São Paulo, SP, Brazil
Hospital de Base de Sao Jose do Rio Preto
🇧🇷Sao Jose do Rio Preto, SP, Brazil
Hanyang University Guri Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
CHA Bundang Medical Centre; CHA university
🇰🇷Seongnam, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Universitaetsklinikum Tuebingen
🇩🇪Tuebingen, Germany
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Northwestern University-Feinberg School of Medicine; Division of Gastroenterology and Hepatology
🇺🇸Chicago, Illinois, United States
Shakespeare Specialist Group
🇳🇿Takapuna, New Zealand
Gemeinschaftspraxis
🇩🇪Offenburg, Germany
Whipps Cross Hospital
🇬🇧London, United Kingdom
Tauranga Hospital
🇳🇿Tauranga, New Zealand
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
University of North Carolina At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
McGuire Research Institute; Gastroenterology
🇺🇸Richmond, Virginia, United States
UZ Brussel
🇧🇪Brussel, Belgium
Hospital Erasme
🇧🇪Bruxelles, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
(G.I.R.I.) GI Research Institute
🇨🇦Vancouver, British Columbia, Canada
Footscray Hospital; Gastroenterology
🇦🇺Footscray, Victoria, Australia
Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz es Szakrendelo
🇭🇺Budapest, Hungary
Baltic Medicine
🇷🇺St.Petersburg, Leningrad, Russian Federation
Military Medical Academy
🇷🇸Belgrade, Serbia
North-Western Medical University n.a. I.I. Mechnikov; Rheumatology
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
SBEIHPE Novosibirsk State Medical University
🇷🇺Novosibirsk, Russian Federation
BHI of Omsk region Clinical Oncology Dispensary
🇷🇺Omsk, Russian Federation
Railway Transport Odesa CH of Healthcare Ctr Branch of PJSC Ukrainian Railway Dept of Therapy #2
🇺🇦Odesa, Ukraine
M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU
🇺🇦Vinnytsia, Ukraine
Zeidler Ledcor Centre - University of Alberta; Division of Gasroenterology
🇨🇦Edmonton, Alberta, Canada
Bankstown-Lidcombe Hospital
🇦🇺Bankstown, New South Wales, Australia
University Hospital - London Health Sciences Centre
🇨🇦London, Ontario, Canada
Royal University Hospital
🇨🇦Saskatoon, Saskatchewan, Canada
Royal Liverpool University Hospital
🇬🇧Liverpool, United Kingdom